Author

Mamoru Watanabe

SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY
SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY

Mamoru Watanabe  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Mamoru Watanabe  et al.

APL DOWNREGULATION IN T CELLS IN THE SETTING OF CHRONIC COLITIS
APL DOWNREGULATION IN T CELLS IN THE SETTING OF CHRONIC COLITIS

Mamoru Watanabe  et al.

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

Mamoru Watanabe  et al.

A CASE OF VILLOUS ATROPHY WITH CCR4+ T CELL INFILTRATION IN THE SMALL INTESTINE
A CASE OF VILLOUS ATROPHY WITH CCR4+ T CELL INFILTRATION IN THE SMALL INTESTINE

Mamoru Watanabe  et al.

ANALYSIS OF GENE EXPRESSION TO ELUCIDATE THE PATHOGENESIS OF PANCREATIC SOLID PSEUDOPAPILLARY NEOPLASM
ANALYSIS OF GENE EXPRESSION TO ELUCIDATE THE PATHOGENESIS OF PANCREATIC SOLID PSEUDOPAPILLARY NEOPLASM

Mamoru Watanabe  et al.

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Mamoru Watanabe  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Mamoru Watanabe  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Mamoru Watanabe  et al.

Item 1 - 9 / 9
1